

Safety and Tolerability of Ecopipam in Tourette Syndrome With Psychiatric Comorbidities

Donald L. Gilbert, MD, MS¹; Frederick E. Munschauer, MD²; George B. Karknias, PhD²; Sarah D. Atkinson, MD²; Stephen P. Wanaski, PhD³; Timothy M. Cunniff, PharmD³


¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH; ²Emalex Biosciences, Inc., Chicago, IL; ³Paragon Biosciences, LLC, Chicago, IL

POSTER
NUMBER:
001

BACKGROUND

- Patients with Tourette syndrome (TS) commonly have comorbid psychiatric conditions (eg, anxiety disorders [ANX], attention-deficit/hyperactivity disorder [ADHD], depression, and obsessive-compulsive disorder [OCD])^{1,2} that may influence TS-related treatment decisions
- Ecopipam is a first-in-class, potent, selective human dopamine D1 receptor antagonist being investigated for the treatment of TS³
- In a phase 2b trial (DIAMOND), ecopipam tablets (2 mg/kg/day) improved the Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) by 30% from baseline at Week 12 in patients with TS, with significance versus placebo ($P=0.01$)³
 - In subset of the 149 (62.4%) patients who had a medical history of ADHD, ANX, or OCD, these comorbid conditions did not impact the efficacy of ecopipam for TS tic reduction (ie, improvement from baseline in YGTSS-TTS at Week 12) versus placebo (**Figure 1**)⁴

Figure 1. Efficacy of Ecopipam Versus Placebo in Patients With and Without Psychiatric Comorbidities⁴



OBJECTIVE

- To assess if ecopipam effects measures of psychiatric comorbidities (ADHD, ANX, depression, and OCD) over the course of the trial

METHODS

- Post hoc subgroup analysis included patients from the phase 2b, randomized, double-blind, placebo-controlled DIAMOND trial aged ≥6 to <18 years with confirmed TS and YGTSS-TTS ≥20 at screening²
 - ANX, ADHD, antidepressants, and OCD medications were permitted if dosage was stable for ≥4 weeks before screening and not specifically prescribed for neurologic symptoms of TS
 - Patients were randomly assigned to ecopipam or placebo for a 4-week titration period, an 8-week maintenance period, and a taper period (**Figure 2**)

Figure 2. Study Design





Figure reproduced from Gilbert DL, et al.³

- Psychiatric comorbidities were assessed by the Swanson, Nolan, and Pelham questionnaire (SNAP-IV); SNAP-IV Connor Index Questionnaire; Pediatric Anxiety Rating Scale (PARS); Children's Depression Rating Scale-Revised (CDRS-R); and the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) scores at baseline and Weeks 4, 6, 8, and 12
- In the current analysis, patients were subgrouped post hoc by presence or absence of baseline psychiatric comorbidities (ie, ANX [generalized or social anxiety, elective/selective mutism, and anxiety disorders not otherwise specified], ADHD, depression, and OCD [both single and multiple diagnoses])
 - Psychiatric comorbidities were identified based on investigator-completed case report forms of medical history and psychiatric (which asked specifically about ADHD and OCD) history
- Changes from baseline with ecopipam versus placebo were compared using a mixed model for repeated measures analysis of covariance model with an unstructured covariance matrix that included the following terms: baseline value, region, age group (6-11 y and 12-17 y), visit, treatment group, and visit-by-treatment interaction

- 149 patients were included in the analysis, with the majority (66.4%) of patients having ≥1 comorbid condition of ADHD, ANX, depression, and OCD (**Figure 3**)
 - The most common psychiatric comorbidities were ADHD (49.0%) and ANX (34.2%)

Figure 3. Patients With Psychiatric Comorbidities




ADHD = attention-deficit/hyperactivity disorder; ANX = anxiety disorders; OCD = obsessive-compulsive disorder; TS = Tourette syndrome.

- Serial assessment showed that 12 weeks of ecopipam did not significantly negatively impact measures of ANX, ADHD, depression, or OCD versus placebo in patients with TS with or without the comorbid condition of interest (**Figures 4A-D** and **5A-D**)
 - No significant differences from baseline were observed between ecopipam and placebo for all subscales of SNAP-IV in patients with or without comorbid ADHD (data not shown)
 - In addition, no significant negative impact was observed with ecopipam versus placebo across the 12 weeks versus baseline for SNAP-IV Connor Index Questionnaire score in patients with (difference ecopipam – placebo LSM [SE] = -0.1 [0.1]; $P=0.43$) or without (LSM [SE] = 0.0 [0.1]; $P=0.84$) comorbid ADHD
 - Of note, in the small subgroup of patients with comorbid depression (n=11), ecopipam significantly improved CDRS-R scores from baseline compared with placebo (**Figure 5A**)

RESULTS

Figure 4. Change in SNAP-IV Scale Score in Patients With (A) or Without (B) Comorbid ADHD and Change in PARS Score in Patients With (C) or Without (D) Comorbid Anxiety



ADHD = attention-deficit/hyperactivity disorder; ANX = anxiety disorders; Eco = ecopipam; LSM = least-squares mean; PARS = Questionnaire, Pediatric Anxiety Rating Scale; PBO = placebo; SNAP-IV = The Swanson, Nolan, and Pelham questionnaire; TS = Tourette syndrome.

Figure 5. Change in CDRS-R Scale Score in Patients With (A) or Without (B) Comorbid Depression and Change in CY-BOCS Score in Patients With (C) or Without (D) Comorbid OCD



CDRS-R = Children's Depression Rating Scale-Revised; CY-BOCS = Children's Yale-Brown Obsessive Compulsive Scale; Eco = ecopipam; LSM = least-squares mean; OCD = obsessive-compulsive disorder; PBO = placebo; TS = Tourette syndrome.

CONCLUSIONS

- Ecopipam has previously been shown to significantly improve symptoms of TS³
- Compared to placebo, ecopipam was not associated with worsening of ADHD, ANX, depression, or OCD comorbidities during the trial
- A phase 3 trial of ecopipam focused on the treatment of TS in pediatric patients aged ≥6 to <18 years is ongoing (NCT05615220)

REFERENCES: 1. Johnson KA, et al. *Lancet Neurol*. 2023;22(2):147-158. 2. Hirschtritt ME, et al. *JAMA Psychiatry*. 2015;72(4):325-333. 3. Gilbert DL, et al. *Pediatrics*. 2023;151(2):e2022059574. 4. Atkinson SD, et al. Presented at American Psychiatric Association Annual Meeting; May 20-24, 2023; San Francisco, CA.

ACKNOWLEDGMENTS: This trial and post analyses were funded by Emalex Biosciences, Inc. Technical editorial and medical writing assistance were provided under direction of the authors by Mary Beth Moncrief, PhD, Synchro Medical Communications, LLC, West Chester, PA. Funding for this assistance was provided by Emalex Biosciences, Inc. Statistical strategy, design, and analysis plans were guided by Richard M. Bittman, PhD, Bittman Biostat, Inc., Naples, FL, with funding support from Emalex Biosciences, Inc.

DISCLOSURES: DLG reports being a clinical trial site investigator for Emalex Biosciences, Inc., and PTC Therapeutics. TMC and SPW are employees of Paragon Biosciences, LLC, a company that founded Emalex Biosciences, Inc. FEM, GBK, and SDA are employees of Emalex Biosciences, Inc.

